DHR Danaher Corporation Loading...

From TMO earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Jan 29 ◎
Mark Casper Chairman and CEO, Thermo Fisher Scientific Inc TMO Q4 FY25 call
Thermo Fisher's bioproduction business delivered 'excellent growth' for another quarter, signaling sustained demand for single-use technologies and cell culture media. — Ongoing bioprocessing demand suggests peer companies in biologics manufacturing supplies (Danaher, Sartorius) may also see tailwinds.
DHR
MED
08:30
Oct 22 ◎
Mark Masper CEO, Thermo Fisher Scientific Inc TMO Q3 FY25 call
Thermo Fisher's new Mebane, NC facility can produce 40 million pipette tips per week, directly addressing U.S. lab consumable supply chain resilience. — Increases domestic capacity and may reduce reliance on Asian suppliers, pressuring competitors in the lab consumables space.
DHR
MED

About DHR Analyst Coverage

Buzzberg tracks DHR (Danaher Corporation) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 2 total trade ideas tracked. Latest voices: Mark Casper, Mark Masper.